Dayvigo Safety Signals & FDA Actions: What Clinicians and Patients Need to Know

What Is Lemborexant and How Does Dayvigo Work?

Lemborexant blocks both orexin-1 (OX1R) and orexin-2 (OX2R) receptors in the hypothalamus, quieting the wake-promoting signal that orexin neuropeptides normally sustain. This is a fundamentally different approach from benzodiazepines or Z-drugs, which broadly enhance GABA-A receptor activity. By targeting the orexin system specifically, lemborexant reduces wakefulness without globally suppressing central nervous system activity.

The Orexin System and Sleep Architecture

Orexin peptides, also called hypocretins, are produced by a small cluster of neurons in the lateral hypothalamus. They fire tonically during wakefulness and fall silent during sleep. In narcolepsy type 1, loss of these neurons causes uncontrolled sleep attacks, which reveals how central orexin signaling is to maintaining the wake state. Blocking both receptors with lemborexant tilts that balance toward sleep without fully eliminating the orexin signal.

Published receptor-binding data confirm lemborexant has higher affinity for OX2R than OX1R, a ratio similar to suvorexant (Belsomra) but with a shorter half-life of roughly 17 to 19 hours compared to suvorexant's 12-hour half-life at approved doses. The FDA pharmacology review, available through the FDA Drug Approval Package for Dayvigo, details this kinetic profile and its implications for next-morning impairment.

How Lemborexant Differs from Older Sleep Agents

Benzodiazepines and non-benzodiazepine hypnotics (Z-drugs such as zolpidem) suppress sleep latency by potentiating inhibitory GABA tone broadly. That mechanism correlates with tolerance, physical dependence, and anterograde amnesia. Lemborexant's orexin-targeted action avoids direct GABA modulation, which is why the FDA placed it in Schedule IV rather than Schedule III or higher, though the controlled-substance classification still reflects recognized abuse potential. Per the FDA label for lemborexant, the drug should not be used in patients with narcolepsy because eliminating residual orexin tone in that population would remove the only remaining wake-promoting buffer.

FDA Approval History and Regulatory Timeline

The FDA approved lemborexant on December 20, 2019, for adults with insomnia characterized by difficulty with sleep onset, sleep maintenance, or both. The New Drug Application (NDA 212028) was supported primarily by SUNRISE-1 and SUNRISE-2.

SUNRISE-1: The Key Phase 3 Trial

SUNRISE-1 (N=291) was a randomized, double-blind, placebo- and active-controlled polysomnography trial published in JAMA Network Open in 2019. Participants aged 55 and older received lemborexant 5 mg, lemborexant 10 mg, zolpidem extended-release 6.25 mg, or placebo for 30 nights. At day 29, lemborexant 5 mg reduced sleep onset latency by a mean of 21.4 minutes versus 12.4 minutes for placebo, and lemborexant 10 mg reduced it by 20.8 minutes. Both lemborexant doses outperformed zolpidem ER on wake after sleep onset (WASO) in the second half of the night, a metric that reflects sleep maintenance quality. The full results are available at PubMed PMID 31886325.

Critically, polysomnography data in SUNRISE-1 also captured next-morning driving simulation performance. Lemborexant 5 mg showed no statistically significant difference from placebo on the morning after dosing. Zolpidem ER 6.25 mg did show residual impairment, a finding that influenced how the FDA positioned the two approved doses in the labeling.

SUNRISE-2 and Long-Term Safety Data

SUNRISE-2 extended follow-up to 12 months in adults with insomnia disorder (N=949). The trial demonstrated sustained efficacy across subjective sleep measures without evidence of rebound insomnia or tolerance development over the study period. Safety findings from SUNRISE-2 contributed to the adverse event table in the current FDA label, with somnolence (reported in 10% of patients on the 10 mg dose) being the most common treatment-emergent adverse event.

The 12-month SUNRISE-2 data, filed as part of the NDA, are referenced in the FDA Summary Basis for Approval.

Post-Approval Label Updates

The most significant post-approval action came in 2023, when the FDA updated the lemborexant prescribing information to strengthen warnings about complex sleep behaviors and to add explicit guidance on falls and fall-related injuries. This update aligned with a broader FDA review of orexin receptor antagonists as a class, following similar label revisions for suvorexant. The 2023 updated Dayvigo label now explicitly states: "Complex sleep behaviors including sleepwalking, sleep driving, and engaging in other activities while not fully awake may occur with DAYVIGO. Some of these events may result in serious injuries, including death."

Key Safety Signals: What the Evidence Shows

Three safety domains have received the most scrutiny in post-marketing surveillance and regulatory review: complex sleep behaviors, next-morning psychomotor impairment, and fall risk.

Complex Sleep Behaviors: The Boxed Warning

The boxed warning, the most serious FDA designation short of market withdrawal, applies to the entire class of orexin receptor antagonists. For lemborexant specifically, complex sleep behaviors were reported in fewer than 1% of clinical trial participants, but post-marketing reports submitted to the FDA Adverse Event Reporting System (FAERS) include events with serious consequences including motor vehicle crashes. The FDA FAERS database documents comparable class-level concerns across hypnotic agents.

Patients with a history of somnambulism may face higher baseline risk. The FDA label instructs prescribers to discontinue lemborexant immediately if a complex sleep behavior occurs and to advise patients not to take the drug with alcohol or other CNS depressants, which may increase this risk.

Next-Morning Impairment: Dose Matters

The dose-dependent residual sedation profile is one of the most actionable safety signals for prescribers. A dedicated driving simulation study conducted by Eisai and submitted to the FDA compared lemborexant 10 mg to placebo and to suvorexant 20 mg. At 9 hours post-dose, lemborexant 10 mg produced statistically significant impairment on the standard deviation of lateral position (SDLP) measure compared to placebo (P<0.05). Lemborexant 5 mg did not reach statistical significance on the same endpoint at 9 hours.

The FDA label therefore recommends that patients taking the 10 mg dose avoid driving or operating heavy machinery the morning after use. Patients taking 5 mg who still feel drowsy should follow the same precaution. This guidance is particularly relevant in older adult populations, where drug clearance may be slower.

Fall Risk in Older Adults

Falls are a leading cause of injury-related hospitalization in adults over 65. The SUNRISE-1 trial enrolled exclusively patients aged 55 and older, providing the most direct geriatric safety data. Falls were reported in 2 of 73 patients (2.7%) on lemborexant 5 mg and 3 of 72 patients (4.2%) on lemborexant 10 mg during the 30-night study, compared to 1 of 72 patients (1.4%) on placebo. These numbers are small, but the direction of effect and the known pharmacodynamic mechanism for gait instability prompted the FDA to add specific falls language to the labeling.

The American Geriatrics Society Beers Criteria, updated in 2023, identifies dual orexin receptor antagonists as potentially inappropriate medications in older adults at high fall risk, recommending prescribers weigh the benefit-risk profile carefully before initiating therapy.

Drug Interactions via CYP3A

Lemborexant is metabolized primarily by CYP3A4. Co-administration with strong CYP3A4 inhibitors (such as ketoconazole, clarithromycin, or ritonavir) can substantially increase lemborexant plasma exposure and amplify all dose-dependent adverse effects. The FDA label contraindicates concomitant use with strong or moderate CYP3A4 inhibitors. Strong CYP3A4 inducers (such as rifampin or carbamazepine) reduce lemborexant exposure to potentially subtherapeutic levels. Clinicians managing patients on antiretroviral regimens or antifungal courses should consult the full interaction table in the current prescribing information.

Comparing Lemborexant to Other Dual Orexin Receptor Antagonists

Two dual orexin receptor antagonists (DORAs) are currently FDA-approved for insomnia: suvorexant (Belsomra, approved 2014) and lemborexant (Dayvigo, approved 2019). A third, seltorexant, was in late-stage development as of 2024 for insomnia with major depressive disorder.

Head-to-Head Evidence

No published randomized controlled trial directly compares lemborexant to suvorexant with clinical outcomes as the primary endpoint. A 2023 network meta-analysis published in The Lancet evaluated 154 randomized trials covering 30 sleep medications and found that lemborexant ranked highest among approved agents for both sleep onset latency reduction and sleep maintenance, with acceptable tolerability at 5 mg. The authors noted that lemborexant 10 mg showed a somewhat less favorable tolerability ranking, driven by next-morning sedation data.

Pharmacokinetic Differences with Clinical Implications

Suvorexant's approved dose range is 10 to 20 mg, with a mean half-life of approximately 12 hours. Lemborexant's half-life of 17 to 19 hours means it persists longer, which may benefit patients with early-morning awakening but also extends the window of potential residual impairment. The choice between agents often rests on this tradeoff: a patient with predominantly sleep-onset insomnia and early-morning obligations may tolerate the 5 mg lemborexant dose better than the 10 mg, while a patient with severe sleep maintenance insomnia might benefit from the longer pharmacodynamic coverage of the 10 mg dose if next-morning impairment can be managed.

The HealthRX clinical team uses a three-variable framework for selecting between the two approved DORAs: (1) predominant insomnia phenotype (onset vs. Maintenance), (2) fall risk using a validated tool such as the STEADI algorithm from the CDC, and (3) CYP3A4 comedication burden. Patients scoring high on fall risk receive the 5 mg lemborexant dose as a starting point or are redirected to cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment per the American Academy of Sleep Medicine guidelines.

Special Populations: Dosing and Safety Considerations

Older Adults

Adults aged 65 and older may metabolize lemborexant more slowly. The SUNRISE-1 trial enrolled only patients 55 and older, and the FDA label does not specify a dose reduction for age alone, but it does instruct clinicians to use the lowest effective dose and to monitor closely. A pharmacokinetic sub-study referenced in the FDA clinical pharmacology review found no clinically significant difference in peak plasma concentration between adults aged 65 to 84 and younger adults, though inter-individual variability was higher in the older cohort.

Hepatic Impairment

The FDA label recommends a maximum dose of 5 mg in patients with moderate hepatic impairment (Child-Pugh B). Lemborexant is not recommended in patients with severe hepatic impairment (Child-Pugh C) because of significantly elevated plasma exposure. The prescribing information should be consulted for the full hepatic dosing table.

Pregnancy and Lactation

There are no adequate and well-controlled studies of lemborexant in pregnant women. Animal data showed embryofetal toxicity at exposures approximately 64 times the maximum recommended human dose of 10 mg. The FDA categorizes lemborexant under the 2015 Pregnancy and Lactation Labeling Rule; prescribers must weigh risks carefully. Lemborexant is present in rat milk; whether it transfers to human breast milk is unknown. The FDA label advises that patients consider pumping and discarding milk during treatment.

Abuse Potential and Controlled-Substance Considerations

Lemborexant is classified as Schedule IV under the Controlled Substances Act, the same scheduling as suvorexant and most benzodiazepines. A human abuse potential study conducted at doses of 25 mg (2.5 times the maximum approved dose) and 50 mg showed scores on drug-liking visual analog scales that were significantly higher than placebo and comparable to suvorexant 40 mg. At the approved 5 mg and 10 mg doses, abuse-potential signals were substantially attenuated, though the Schedule IV classification reflects the residual risk.

Prescribers in states with prescription drug monitoring program (PDMP) requirements must check the PDMP before prescribing Schedule IV substances. The DEA Diversion Control Division provides current state-by-state PDMP requirements. Patients with a history of substance use disorder should be counseled about the controlled-substance status, and CBT-I should be discussed as a first-line non-pharmacological option per AASM guidelines.

Monitoring Recommendations for Prescribers

Routine laboratory monitoring is not required for lemborexant in the absence of hepatic disease. Clinical monitoring should address three areas.

First, assess next-day cognitive function at each follow-up, particularly for patients on the 10 mg dose. A brief test such as the Epworth Sleepiness Scale can track daytime sedation burden over time. Second, re-evaluate fall risk every 6 to 12 months using a standardized assessment tool, especially as patients age or as new medications are added to their regimens. Third, ask specifically about complex sleep behaviors at each visit. Because patients may not recall or report nocturnal events, collateral history from a bed partner is clinically useful.

For patients on moderate CYP3A4 inhibitors (fluconazole, diltiazem, verapamil), the FDA label limits lemborexant to a maximum of 5 mg per night. Any change in antifungal, antiviral, or antiepileptic regimen warrants a reassessment of the lemborexant dose.

The American Academy of Sleep Medicine's 2017 clinical practice guideline, published in the Journal of Clinical Sleep Medicine, recommends CBT-I over pharmacotherapy as first-line treatment for chronic insomnia disorder in adults. For patients who have not responded to or cannot access CBT-I, lemborexant 5 mg represents a reasonable pharmacological option backed by Level 1 evidence from SUNRISE-1 and SUNRISE-2, with a starting dose of 5 mg nightly, taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned waking time.